FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase ...

(RTTNews) - Arcutis Biotherapeutics Inc.'s (ARQT) ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of atopic dermatitis in individuals regardless of race, ...

NBC Select independently determines what we cover and recommend. When you click on or buy through our links, we earn a commission. Learn more. Bethany Heitman Contributing Editor We don’t always have ...

Discover safe hair removal tips for eczema-prone skin, including best methods, skin prep, product choices, and aftercare.

Add Yahoo as a preferred source to see more of our stories on Google. It’s been said before and it’s true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes ...

Biotech stock Arcutis is in a buy zone and Wall Street is looking for the skin-diseases drugmaker to expand the use of its ...

For individuals living with eczema, a skin care routine centered on gentle, skin barrier-restoring products can help manage the symptoms brought on by a flare. “Eczema is a chronic inflammatory ...

Twice-daily application of 1.5% ruxolitinib cream was found to be effective in children and adolescents with atopic dermatitis and vitiligo. Children and adolescents with atopic dermatitis (AD) and ...

Arcutis Biotherapeutics said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its Zoryve topical treatment for infants with atopic dermatitis, the most ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. More than a quarter of patients achieved a clear or ...

WESTLAKE VILLAGE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...